奥浦迈股价涨5.02%，工银瑞信基金旗下1只基金位居十大流通股东，持有330.01万股浮盈赚取811.82万元

Group 1 - The core viewpoint of the news is that Aopumai's stock price increased by 5.02% to 51.46 CNY per share, with a trading volume of 27.03 million CNY and a turnover rate of 0.47%, resulting in a total market capitalization of 5.857 billion CNY [1] - Aopumai Biotechnology Co., Ltd. is located in Shanghai and was established on November 27, 2013, with its listing date on September 2, 2022. The company's main business involves cell culture products and services, with revenue composition being 87.34% from products, 12.53% from services, and 0.13% from other sources [1] Group 2 - From the perspective of Aopumai's top ten circulating shareholders, a fund under ICBC Credit Suisse, namely ICBC Frontier Medical Stock A (001717), increased its holdings by 400,000 shares, totaling 3.3001 million shares, which represents 2.91% of the circulating shares. The estimated floating profit today is approximately 8.1182 million CNY [2] - ICBC Frontier Medical Stock A (001717) was established on February 3, 2016, with a latest scale of 9.636 billion CNY. Year-to-date return is 17.03%, ranking 3002 out of 4189 in its category; the one-year return is also 17.03%, with the same ranking; since inception, the return is 207.9% [2] - The fund manager of ICBC Frontier Medical Stock A is Zhao Bei, who has a cumulative tenure of 11 years and 52 days, managing total assets of 17.223 billion CNY, with the best fund return during the tenure being 207.9% and the worst being -33.69% [2]